Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study

Introduction For hemodialysis patients at high risk of bleeding, a regional anticoagulant can be used, such as citrate or nafamostat mesylate (NM). The objective of this study was to evaluate NM as an alternative to citrate for anticoagulation in hemodialysis patients at high risk of bleeding.Method...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Renal Failure
المؤلفون الرئيسيون:	Jiangtao Li, Lirui Wang, Yuqiu Lu, Ying Zhou, Yue Chen
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Taylor & Francis Group 2025-12-01
الموضوعات:	Hemodialysis anticoagulation nafamostat mesylate citrate
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/0886022X.2025.2464830

مواد مشابهة

Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study
حسب: Dan Liu, وآخرون
منشور في: (2024-01-01)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
حسب: Weiwei Qian, وآخرون
منشور في: (2023-09-01)

Anticoagulation application of nafamostat mesylate in patients on continuous renal replacement therapy at a high risk of hemorrhage
حسب: Jia-rong Ding, وآخرون
منشور في: (2024-02-01)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
حسب: Takahiro Hirayama, وآخرون
منشور في: (2017-07-01)

Comparison of circuit patency and exchange rates between the original and generic versions of nafamostat mesylate in critically ill adults receiving continuous renal replacement therapy
حسب: Sujung Heo, وآخرون
منشور في: (2023-03-01)

Nafamostat mesylate augments survival in rats afflicted by exertional heat stroke
حسب: Qingwei Lin, وآخرون
منشور في: (2025-05-01)

Application of nafamostat mesylate in 5 cases of extracorporeal carbon dioxide removal combined with continuous renal replacement therapy
حسب: Ma Xiaobo, وآخرون
منشور في: (2025-09-01)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
حسب: Shinya Kameda, وآخرون
منشور في: (2023-01-01)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
حسب: Yuxin Zhang, وآخرون
منشور في: (2020-08-01)

Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
حسب: Pei Xie, وآخرون
منشور في: (2025-03-01)

Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study
حسب: Shinya Kameda, وآخرون
منشور في: (2024-02-01)

Integration of transcriptomics and metabolomics reveals the molecular mechanisms underlying the effect of nafamostat mesylate on rhabdomyolysis-induced acute kidney injury
حسب: Wenli Guo, وآخرون
منشور في: (2022-11-01)

Application of regional citrate anticoagulation to patients with hemodialysis at high risk of bleeding
حسب: WANG Kui, وآخرون
منشور في: (2018-01-01)

How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes
حسب: Yiqi Qian, وآخرون
منشور في: (2024-09-01)

Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report
حسب: Yasuhito Suzuki, وآخرون
منشور في: (2024-01-01)

Effect of nafamostat in continuous renal replacement therapy for patients at risk of bleeding
حسب: TANG Xiaofang*, ZHANG Xu, JIANG Chunming, ZHANG Xijun, TANG Peng, LI Kangfeng
منشور في: (2025-04-01)

Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats
حسب: Ji-Hyun Kang, وآخرون
منشور في: (2021-09-01)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
حسب: Hyeon-A Kim, وآخرون
منشور في: (2022-06-01)

Observation of the efficacy of long-term citrate anticoagulation in patients with maintenance hemodialysis
حسب: ZHUANG Feng, وآخرون
منشور في: (2020-01-01)

Measuring the Concentration of Serum Syndecan-1 to Assess Vascular Endothelial Glycocalyx Injury During Hemodialysis
حسب: Keigo Kusuzawa, وآخرون
منشور في: (2021-12-01)

Comparative observation of anticoagulant effect of simplified-regional citrate and argatroban in patients with hemodialysis at high risk of bleeding
حسب: QIU De-jun, وآخرون
منشور في: (2020-01-01)

Deciphering simplified regional anticoagulation with citrate in intermittent hemodialysis: a clinical and computational study
حسب: Julien Aniort, وآخرون
منشور في: (2024-08-01)

Nafamostat mesilate attenuates renal fibrosis by suppressing the IL-17 signaling pathway
حسب: Weili Liao, وآخرون
منشور في: (2025-10-01)

Clinical observation of two-stage regional citrate anticoagulation in hemodialysis with high risk of bleeding
حسب: XI Chun-sheng, وآخرون
منشور في: (2018-01-01)

Clinical observations on anticoagulant efficacy of high-dose segmented citrate on high-flux hemodialysis
حسب: Ke Xiao-su, وآخرون
منشور في: (2021-01-01)

Pharmacokinetic and pharmacodynamic analyses of nafamostat in ECMO patients: comparing central vein and ECMO machine samples
حسب: Dong Hwan Lee, وآخرون
منشور في: (2025-05-01)

Heparin anticoagulation versus regional citrate anticoagulation for membrane therapeutic plasma exchange in patients with increased bleeding risk
حسب: Jing Jiao, وآخرون
منشور في: (2023-12-01)

Comparison of regional citrate anticoagulation and nafamostat mesylate anticoagulation during plasma exchange for children at high bleeding risk: a retrospective study
حسب: Dan Peng, وآخرون
منشور في: (2025-04-01)

Effects of low molecular weight heparin sodium and sodium citrate on hemodialysis patients at high risk of bleeding: a comparative study
حسب: Juan YUAN
منشور في: (2022-01-01)

Construction and validation of a prediction model for the risk of citrate accumulation in patients with hepatic insufficiency receiving continuous renal replacement therapy with citrate anticoagulation
حسب: Quxia Hong, وآخرون
منشور في: (2024-01-01)

Serum Lactate Levels and Kinetics Predict Citrate Accumulation in Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy
حسب: Harmony Hau Man To, وآخرون
منشور في: (2025-08-01)

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
حسب: Megan Neary, وآخرون
منشور في: (2023-08-01)

The SARS-CoV-2 Entry Inhibition Mechanisms of Serine Protease Inhibitors, OM-85, Heparin and Soluble HS Might Be Linked to HS Attachment Sites
حسب: Antony Cheudjeu
منشور في: (2022-03-01)

Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial
حسب: Hongyu Yang, وآخرون
منشور في: (2025-07-01)

Regional citrate anticoagulation for continuous renal replacement therapy in newborns
حسب: Haixia Huang, وآخرون
منشور في: (2023-03-01)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
حسب: Yao Lin, وآخرون
منشور في: (2022-12-01)

Regional citrate anticoagulation (RCA) in critically ill patients undergoing renal replacement therapy (RRT): expert opinion from the SIAARTI-SIN joint commission
حسب: Valentina Pistolesi, وآخرون
منشور في: (2023-03-01)

Determinants of Calcium Infusion Rate During Continuous Veno-venous Hemofiltration with Regional Citrate Anticoagulation in Critically Ill Patients with Acute Kidney Injury
حسب: De-Lin Liu, وآخرون
منشور في: (2016-01-01)

Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice
حسب: Hirofumi Matsubara, وآخرون
منشور في: (2022-01-01)

Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate
منشور في: (2009-09-01)